Immuneering (IMRX) Total Current Liabilities (2020 - 2024)
Historic Total Current Liabilities for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $6.9 million.
- Immuneering's Total Current Liabilities rose 2308.11% to $6.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $6.9 million, marking a year-over-year increase of 2308.11%. This contributed to the annual value of $7.8 million for FY2023, which is 258.96% down from last year.
- Latest data reveals that Immuneering reported Total Current Liabilities of $6.9 million as of Q3 2024, which was up 2308.11% from $6.8 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Total Current Liabilities peaked at $8.1 million during Q4 2022, and registered a low of $2.3 million during Q4 2020.
- Moreover, its 5-year median value for Total Current Liabilities was $5.5 million (2023), whereas its average is $5.6 million.
- In the last 5 years, Immuneering's Total Current Liabilities soared by 14974.28% in 2021 and then plummeted by 2251.3% in 2023.
- Quarter analysis of 5 years shows Immuneering's Total Current Liabilities stood at $2.3 million in 2020, then surged by 149.74% to $5.6 million in 2021, then soared by 42.96% to $8.1 million in 2022, then dropped by 2.59% to $7.8 million in 2023, then decreased by 11.8% to $6.9 million in 2024.
- Its Total Current Liabilities was $6.9 million in Q3 2024, compared to $6.8 million in Q2 2024 and $5.2 million in Q1 2024.